ARTICLE | Company News

Atrix, CollaGenex, Block Drug Co. Inc. deal

September 4, 2001 7:00 AM UTC

ATRX reobtained rights from Block to its dental products, including its Atridox periodontal disease products, for $7 million, $3.3 million of which ATRX will pay upfront and the remainder of which will come from Atridox sales over four years. In addition, Block will pay ATRX $3 million for the development and approval of Atrisorb-D for use in gingival surgery. ATRX said the deal terminates all ongoing legal proceedings between the companies (see BioCentury, April 30). ...